drugset
drugset / Trial / NCT03496974

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

NCT03496974 ↗

Phase 2 Completed 38 enrolled Janssen Research & Development, LLC
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 2 study of Bermekimab (MABp1) in patients with atopic dermatitis.

Timeline

Start
2018-05-21
Primary completion
2018-12-04
Completion
2018-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bermekimab Monoclonal antibody 200 mg Subcutaneous
Subject Bermekimab Monoclonal antibody 400 mg Subcutaneous

Indications

atopic eczema